A major contributor to this article appears to have a close connection with its subject. (April 2024) |
Flemming Ørnskov (born 1957/58) is a Danish businessman. He has been the chief executive officer (CEO) of Galderma[2] since October 2019.
Flemming Ørnskov | |
|---|---|
 | |
| Born | 1957 or 1958 (age 65–66)[1] |
| Nationality | Danish |
| Alma mater | University of Copenhagen INSEAD Harvard University |
| Occupation(s) | CEO, Galderma |
He was previously the CEO of Shire plc, a FTSE 100 specialty biopharmaceutical company as of 30 April 2013, succeeding Angus Russel.[3] He previously worked for Bayer, Bausch & Lomb and Novartis.[2]
He is also the chairman of Waters Corporation.[4]
Ørnskov received his MD from the University of Copenhagen, followed by an MBA from INSEAD, and a Master of Public Health (MPH) from Harvard University.[1]
Awards edit
Top 100 Best-Performing CEOs in the World, 2015 - Harvard Business Review[5]
Top 25 Most Influential People in Biopharma Today, 2013 - Fierce Biotech[6]
References edit
- ^ a b "Executive Profile: Flemming Ornskov". Bloomberg. Retrieved 4 September 2017.
- ^ a b Liu, Angus (October 8, 2019). "Ex-Shire CEO Flemming Ornskov emerges as Galderma CEO after $10B Nestlé spinout". Fiercepharma.
- ^ "Shire chief finds right prescription for growth". The Telegraph. Retrieved 20 March 2014.
- ^ "Conseil d'administration : Waters". www.waters.com. Retrieved 2021-04-01.
- ^ "The 'best-performing' CEO in the world is a pharma chief". BioPharma Dive. Retrieved 2021-04-01.
- ^ "The 25 most influential people in biopharma today - 2013". FierceBiotech. Retrieved 2021-04-01.
  | This Danish biographical article is a stub. You can help Wikipedia by expanding it. |
 | This business-related biographical article is a stub. You can help Wikipedia by expanding it. |